Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 1, 2018

View Archived Issues

Predicting chemotherapy synergies

Repair cells can make things worse in neuromuscular disease

New arthritis severity gene id'd

Mortalin Kombat: Lysosomal inhibitor findings have cancer therapy implications

Award for Logic Biosciences' LBS-101 for oral mucositis

Mouse model reveals role of amylin signaling in POMC neurons in food intake, energy metabolism

Circadian regulation through MTNR1A contributes to the pathological cascade of Alzheimer's disease

SliC, a lysozyme-binding lipoprotein of N. gonorrhoeae with a key role during host colonization

Gut microbiota-derived metabolite TMAO found elevated in patients with Alzheimer's disease

ABL Bio and I-Mab enter immuno-oncology partnering agreement

Rxulti approved in E.U. for schizophrenia

European Commission approves Pfizer trastuzumab biosimilar Trazimera

Purdue completes phase Ib study of small molecule for insomnia associated with alcohol cessation

Myalepta approved for lipodystrophy in E.U.

Asterias releases Cohort 3 and 4 data from phase I/IIa SCiStar trial in severe spinal cord injury

European Commission approves Xeljanz for ulcerative colitis

Neuralstem begins phase II study of NSI-566 for ischemic stroke

NeuroActiva presents phase I data for NA-831 for Alzheimer's disease

New kinase inhibitors developed at IMPACT Therapeutics

Enanta Pharmaceuticals identifies respiratory syncytial virus inhibitors

ViiV Healthcare UK patents HIV integrase inhibitors

TGF-beta receptor type-1/2 inhibitors discovered at Bristol-Myers Squibb

Renji Hospital synthesizes aaptamine alkaloid derivatives

New phase I trial explores use of CERC-301 for neurogenic orthostatic hypotension in Parkinson's

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...